



Consensus Standards Approval Committee (CSAC) Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that CSAC members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by CSAC members, NQF is requiring the following recusals be made during the November 9-10, 2016 CSAC in-person meeting.

CSAC Member Recusals for Measures Reviewed at the November 9-10, 2016 In-Person Meeting

Measure Number	Measure Title	Measure Steward	NQF Project	CSAC Member Recusals
#0066	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	American Heart Association	Cardiovascular 2016-2017	Henry Ting, Senior Vice President and Chief Quality Officer, New York-Presbyterian
#0288	Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival	CMS	Cardiovascular 2016-2017	Henry Ting, Senior Vice President and Chief Quality Officer, New York-Presbyterian
#0290	Median Time to Transfer to Another Facility for Acute Coronary Intervention	CMS	Cardiovascular 2016-2017	Henry Ting, Senior Vice President and Chief Quality Officer, New York-Presbyterian
#2939	Statin Therapy in Patients with Clinical Atherosclerotic Disease	ACC	Cardiovascular 2016-2017	Henry Ting, Senior Vice President and Chief Quality Officer, New York-Presbyterian